metastasis in primary low-grade ovarian cancer. Further prospective trials evaluating LVS1 and Ki-67 as a predictor of lymph-node metastasis should be planned.

IGCS20_1508

**COMPARISON OF DIFFERENT METHODS TO DETERMINE MYOMETRICAL INVASION IN ENDOMETRIAL CANCER – A NATIONWIDE SWEECG STUDY**


10.1136/ijgc-2020-IGCS.402

**Background** Deep myometrial invasion (MI) (≥50%) is a prognostic factor for lymph node metastases and poorer survival in endometrial cancer. There is no consensus regarding which pre/peroperative diagnostic method should be preferred.

**Aim** To explore the pattern of different diagnostic methods for MI assessment in Sweden and to evaluate differences between MRI, vaginal ultrasound, frozen section and gross examination in clinical practice.

**Methods** Women with endometrial cancer registered in the Swedish Quality Registry for Gynecologic Cancer (SQRGC) between January 2010 and December 2019 were eligible. Inclusion criteria were FIGO stage I-II and available information on histology and on assessment of MI. Data on age, histology, FIGO stage, degree of MI, pathology result, method for MI assessment and hospital level were collected from the SQRGC. The final assessment by the pathologist on specimens from hysterectomy was the standard.

**Results** The study population included 1,950 women, 33% (n=649) had a MI ≥50%. The methods used for MI assessment were vaginal ultrasound in 54%, MRI in 22%, gross examination in 13% and frozen section in 11% of cases. Age, histology or FIGO stage did not differ between the methods. The sensitivity, specificity and accuracy of vaginal ultrasound was 61.2%, 83.3% and 0.75% respectively, and for MRI 74.2%, 72.7% and 0.73%. The highest accuracy was for frozen section; 95.0%.

**Conclusion** The assessment of deep myometrial invasion in endometrial cancer is most often performed with vaginal ultrasound in Sweden. The sensitivity of this method is lower in clinical practice than for MRI and perioperative methods.

IGCS20_1511

**DELAYS IN TREATMENT IN GYNAECOLOGY ONCOLOGY PATIENTS IN QATAR SEEKING MANAGEMENT OVERSEAS**

S Brich*, T Alsayed, A Ansari, H ElMalik, J Herod. Hamad medical corporation, Qatar

10.1136/ijgc-2020-IGCS.403

**Introduction** The gynaecological oncology service in Doha treats all women living in or visiting Qatar. Despite the quality and affordability of the service many women travel overseas for their treatment following diagnosis or present following previous treatment overseas requesting further management. Although they must perceive potential advantages which encourage them to do so, there are difficulties which could arise including delay in treatment of a malignancy that could affect their outcomes. We wished to understand the impact of travel overseas on the waiting time for treatment.

**Methods** All patients seen over a period of 3 yrs who had travelled overseas were identified. Records were reviewed to identify what impact the decision to travel abroad had made on the timing of their treatment. According to Qatari cancer treatment standards, treatment should be within 14 days of a decision made by MDT. We considered that a delay in treatment would reasonably be defined as an interval of >4 weeks.

**Results** 18% of patients (n=153/850) with a recorded care plan by the MDT sought medical treatment overseas between 4/2015 and 3/2018. Patients had 25 different nationalities; Qatari nationals represented the majority (40.5%). Patients travelled to 28 different destinations. Most travelled to the U.S.A (15.7%), Philippines (15%), the UK (10.5%) and Thailand (9.2%).

23.5% of patients had a delay in treatment; 9.2% had an unknown treatment timing plan. Most had delays of <6 weeks; 10% had significant delays of many weeks, months and even >1 year.

**Conclusion** The decision to travel overseas in our patients resulted in delays of treatment for roughly 1/4 of patients. In 10% these delays would be expected to have an adverse effect on outcomes.

IGCS20_1512

**SIMVASTATIN MODIFIES THE INTERNALIZATION, ENDOCYTIC TRAFFICKING, AND THE CONTENT OF OVARIAN CANCER CELLDERIVED EXTRACELLULAR MICROVESICLES WHICH ARE RESPONSIBLE OF INDUCING MIGRATION AND INVASION IN VITRO**


10.1136/ijgc-2020-IGCS.404

**Introduction** High grade serous ovarian carcinoma (HGSOC) is the leading cause of death among all gynecological malignancies. Extracellular microvesicles (MVs) are secreted by most cells in the body and play a crucial role regulating cell-to-cell communication and several biological functions. Current
evidence shows that MV release and its content are modified in cancer cells compared to normal counterpart. By this mean, cancer cells can condition tumor microenvironment allowing them to metastasize, survive when exposed to adverse conditions (i.e. chemotherapy) and evade immune surveillance. Simvastatin (Simv), a HMGCoA reductase inhibitor and beyond its primary property of reducing cholesterol synthesis, exerts a role in cellular signaling and protein trafficking by inhibiting the isoprenylation of small GTPases. Recently, our group has demonstrated that (Simv) reduces metastasis in HGSOC murine models and improve survival among statin users. Here, our aim was to study the effect of simvastatin in MV release from HGSOC cancer cells, the MV composition, its uptake, its intracellular trafficking in neighbor cancer cells and in the MVinduced migration and metastasis of these cells.

Methods HeyA8-released MVs were isolated upon 24h exposition to Simv (5 μM) or MOCK (DMSO as vehicle) by using differential ultracentrifugation, characterized by transmission electron microscopy (TEM) and immunoblotting (Alix, HSP70, TSG101, and CD63), and quantify by nanoparticle tracking analysis (NTA). For the uptake assays, HeyA8 cells were treated with PKH67-labelled MVs (2,5h) and analyzed by flow cytometry. For MV content composition, proteins involved in adhesion and invasion (i.e. EMM-PRIN) were characterized by immunoblotting. The endocytic trafficking was assessed by measuring the colocalization of PKH67-labelled MVs with recycling endosome (Transferrin) and lysosome (Lysotracker) markers by fluorescence microscopy in recipient HeLa cells. For migration and invasion assays HeyA8 cells were incubated with Simv or MOCK-treated MVs for up to 48h.

Results Simv did not modify MV profile and release from HeyA8 cells. However, Simv significantly reduced the EMM-PRIN content in MVs and increased its uptake in recipient cancer cells compared with MOCK conditions. Upon Simv exposure, a shift in intracellular trafficking towards recycling endosomes rather than to lysosomes was observed in these cells. More importantly, a significant reduction in migration and invasion induced by MVs in HeyA8 cancer cells was observed upon Simv exposure.

Conclusion Herein, we demonstrated that MVs released by HGSOC cells exert an autocrine and paracrine effect that prompt migration and invasiveness of cancer cells. Among the mechanisms by which Simv inhibit cancer cell metastasis are the modification in MV content, its uptake and intracellular trafficking, all critical steps for determining their procarcinogenic effects. Our findings provide preliminary and novel evidence on the relevance of Simv in regulating cell-to-cell communication through MVs and further support for considering the use and maintenance of statins in HGSOC patients. (Research support by Fondecyt 1201083 and 1181907).

Surgical Films

Surgical Films

IGCS20_1164

LAPAROSCOPIC MANAGEMENT OF HUGE OVARIAN CYST; NOVEL TECHNIQUE

S Addley*, H Soleymani Majd, M Alazzam. Oxford University Hospitals, UK

This is a case of 35 years old patient who presented with a massive ovarian mass. She underwent fertility-preserving ovarian cystectomy. The technique describes how to manage such ovarian masses while maintaining cancer hygiene and limitation of spillage risks.

IGCS20_1435

VNOTES (VAGINAL NATURAL ORIFICES TRANSLUMINAL ENDOSCOPIC SURGERY) FOR IA1 CERVICAL CARCINOMA

L Badiglian-Filho*, C Chaves Faloppa, E Mieko Fukazawa, G Baiocchi, L Badiglian-Filho, C Chaves Faloppa, E Mieko Fukazawa, G Baiocchi. AC Camargo Cancer Center, Brazil

Introduction The treatment of cervical squamous cell carcinoma, FIGO stage Ia, with no lymphovascular invasion is total hysterectomy with salpingectomy with/without oophorectomy, when there is no intention for fertility-sparing. Lymphadenectomy is usually omitted in those cases. Recently, Ramirez et al evidenced that minimally invasive radical hysterectomy was associated with lower rates of disease-free survival and overall survival than open abdominal radical hysterectomy among women with early-stage cervical cancer. After that work, the uterine manipulator was pointed as an important cause for these results by some authors and many of them proposed...